News Year None20202019201820172016 March 30, 2020 Rhythm Pharmaceuticals Provides Updates on Leadership Transition and Business Operations March 30, 2020 Rhythm Pharmaceuticals Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Setmelanotide in POMC and LEPR Deficiency Obesities March 18, 2020 Rhythm Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for Setmelanotide for the Treatment of Alström Syndrome March 2, 2020 Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results February 25, 2020 Rhythm Pharmaceuticals to Present at Cowen & Co. 40th Annual Health Care Conference January 6, 2020 Rhythm Pharmaceuticals Announces Leadership Transition
March 30, 2020 Rhythm Pharmaceuticals Provides Updates on Leadership Transition and Business Operations
March 30, 2020 Rhythm Pharmaceuticals Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Setmelanotide in POMC and LEPR Deficiency Obesities
March 18, 2020 Rhythm Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for Setmelanotide for the Treatment of Alström Syndrome
February 25, 2020 Rhythm Pharmaceuticals to Present at Cowen & Co. 40th Annual Health Care Conference